Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis

被引：3
|
作者：
Righini, Matteo [1 ,2 ]
Mollica, Veronica [3 ,4 ]
Rizzo, Alessandro [5 ]
La Manna, Gaetano [2 ]
Massari, Francesco [3 ,4 ]
机构：
[1] Santa Maria Croci Hosp, Nephrol & Dialysis Unit, AUSL Romagna, I-48121 Ravenna, Italy
[2] Univ Bologna, Dialysis & Transplantat Unit, Nephrol, IRCCS Azienda Osped Univ Bologna, I-40126 Bologna, Italy
[3] Univ Bologna, Med Oncol, IRCCS Azienda Osped, Via Albertoni 15, I-40138 Bologna, Italy
[4] Univ Bologna, Dept Expt Diagnost & Specialty Med, I-40126 Bologna, Italy
[5] Ist Ric Cura Carattere Sci IRCCS, Struttura Semplice Dipartimentale Oncol Med Presa, I-70124 Bari, Italy
来源：
JOURNAL OF CLINICAL MEDICINE | 2022年 / 11卷 / 15期
关键词：
immune-checkpoint inhibitors; meta-analysis; renal toxicity; PD-1; inhibitors; PD-L1; chronic kidney disease; acute kidney injury; ADVERSE EVENTS; NIVOLUMAB; CHEMOTHERAPY; PEMBROLIZUMAB; DOCETAXEL; RISK; IMMUNOTHERAPY; MULTICENTER; IPILIMUMAB; MELANOMA;
D O I：
10.3390/jcm11154373
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Aim: We performed a meta-analysis of the available clinical trials of immune-checkpoint inhibitors to assess risk differences and relative risks of renal toxicity. Methods: 17 randomized phase III studies were selected, including 10,252 patients. Results: The administration of immune-checkpoint inhibitors resulted in an overall low-grade, high-grade and all-grade renal toxicity Risk Difference of: 0.746% (95% CI 0.629% to 1.15%, p < 0.001-random), 0.61% (95% CI, 0.292-0.929%, p < 0.001-fixed) and 1.2% (95% CI, 0.601-1.85%-random), respectively. The pooled Relative Risk of low-grade, high-grade and all-grade renal toxicity was: 2.185 (95% CI 1.515-3.152-fixed), 2.610 (95% CI, 1.409-4.833, p = 0.002-fixed) and 2.473 (95% CI, 1.782-3.431, p < 0.001-fixed), respectively. An increased risk of renal toxicity was evident in some subgroups more than others. Conclusion: Immune-checkpoint inhibitors are associated with an increased risk of renal toxicity.
引用
收藏
页数：17
相关论文
共 50 条
  • [21] Prognostic and clinicopathological significance of Systemic Immune-Inflammation Index in cancer patients receiving immune checkpoint inhibitors: a meta-analysis
    Wang, Yan
    Ni, Qunqin
    ANNALS OF MEDICINE, 2023, 55 (01) : 808 - 819
  • [22] A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors
    Abdel-Rahman, Omar
    Fouad, Mona
    IMMUNOTHERAPY, 2016, 8 (05) : 665 - 674
  • [23] Meta-Analysis of Quality of Life in Cancer Patients Treated With Immune Checkpoint Inhibitors
    Gonzalez, Brian D.
    Eisel, Sarah L.
    Bowles, Kristina E.
    Hoogland, Aasha, I
    James, Brian W.
    Small, Brent J.
    Sharpe, Susan
    Hyland, Kelly A.
    Bulls, Hailey W.
    Christy, Shannon M.
    Mansfield, Jori
    Nelson, Ashley M.
    Alla, Raviteja
    Maharaj, Kelly
    Kennedy, Brittany
    Lafranchise, Elizabeth
    Williams, Noelle L.
    Jennewein, Sarah
    Oswald, Laura B.
    Postow, Michael A.
    Dicker, Adam P.
    Jim, Heather S. L.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (06): : 808 - 818
  • [24] Efficacy of immune checkpoint inhibitors in cancer patients of different ages: a meta-analysis
    Li, Jing
    Gu, Jian
    FUTURE ONCOLOGY, 2019, 15 (31) : 3633 - 3646
  • [25] Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis
    Kiss, I.
    Kuhn, M.
    Hrusak, K.
    Buchler, T.
    ESMO OPEN, 2022, 7 (03)
  • [26] Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
    Abdel-Rahman, Omar
    Fouad, Mona
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2016, 10 (03) : 183 - 193
  • [27] Quality of life in cancer patients treated with immune checkpoint inhibitors: A meta-analysis
    Gonzalez, B. D.
    Eisel, S. L.
    Bowles, K. E.
    Hoogland, A. I.
    James, B. W.
    Small, B. J.
    Sharpe, S.
    Hyland, K. A.
    Bulls, H. W.
    Christy, S. M.
    Mansfield, J.
    Nelson, A. M.
    Alla, R.
    Maharaj, K.
    Kennedy, B.
    Lafranchise, E.
    Williams, N. L.
    Postow, M. A.
    Dicker, A. P.
    Jim, H. S. L.
    ANNALS OF ONCOLOGY, 2020, 31 : S956 - S956
  • [28] Immune-checkpoint inhibitors in anal squamous cell carcinoma: a systematic review and meta-analysis
    Pala, Laura
    De Pas, Tommaso
    Stucchi, Erika
    Catania, Chiara
    Cocorocchio, Emilia
    Zampino, Maria Giulia
    Rossi, Giovanna
    Zattarin, Emma
    Di Muzio, Antonio
    Laszlo, Daniele
    Stucchi, Sara
    Conforti, Fabio
    SEMINARS IN ONCOLOGY, 2023, 50 (06) : 140 - 143
  • [29] Incidence of thyroid test function abnormalities in patients receiving immune-checkpoint inhibitors for cancer treatment
    Patel, Nisha
    Oury, Anais
    Daniels, Gregory
    Bazhenova, Lyudmila
    Patel, Sandip
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [30] Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment
    Patel, Nisha Subhash
    Oury, Anais
    Daniels, Gregory A.
    Bazhenova, Lyudmila
    Patel, Sandip Pravin
    ONCOLOGIST, 2018, 23 (10): : 1236 - 1241
12345